

Definitive staging and perioperative treatment for resectable Stage IB-IIIA Non-small Cell Lung Cancer (NSCLC): a UK perspective

HSD31

Christine MAI, Dr (MD)¹, Andrei Horia SEFERIAN, Dr (MD)², Stéphane DENIAU, MSc³, Paul TAYLOR, Msc.⁴, Bertrand De Buhren, Dr (Ph)⁵, Sébastien VIARD, Msc.⁵.

¹AplusA Real World, Lyon, France, ²Faculté de Médecine, Université Paris-Saclay, INSERM UMR_S999, Hôpital Bicêtre, Le Kremlin-Bicêtre, Paris, France, ³RWE BU Director - AplusA Real World, A+A SAS, Lyon, France, ⁴AplusA, London, United Kingdom, ⁵AplusA, Lyon, France.

INTRODUCTION

Although early-stage resectable stage IB-IIIA NSCLC has a better prognosis, it is associated with high recurrence rates within the first 5 years, even with chemotherapy (CT) administered pre- or post-surgery¹.

Immunotherapy (IO) has revolutionized the treatment of metastatic NSCLC in the last 10 years, improving survival and providing patients with a better quality of life².

Recently, IO has been used alone or in combination with CT for NSCLC in adjuvant, neoadjuvant, or perioperative settings, with promising results³.

OBJECTIVE


1. Collection of Real-world Data on the Management of Potentially Resectable Stage IB-IIIA Non-small Cell Lung Cancer (NSCLC) in the United Kingdom (UK) in 2023.
2. Evaluation of Early of Immune Checkpoint Inhibitors (ICIs) for this new indication. Adoption.

METHOD


- Anonymous patient charts from oncologists or thoracic surgeons.
- A total of 299 patients who underwent surgery for stage IB to IIIA NSCLC.
- Analysis included comprehensive clinical and biological data collection with a special focus on adjuvant, neoadjuvant and perioperative treatment regimens.

RESULTS

1. DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF THE PATIENTS AT BASELINE



2. PERIOPERATIVE TREATMENT REGIMENS



DISCUSSIONS

- Complete resection was obtained in 85% of the patients, similar to published data³
- Post-operative staging were stage IA – 10% of the cases, stage IB – 20%, stage II – 38% and stage III 31%, respectively.
- Chemo and IO treatment regimens were well tolerated either as neo and/or adjuvant therapy
- The main reason for non prescribing neoadjuvant therapy was that physicians considered it not necessary as recommendations were being updated at that time⁴
- The main reason for non prescribing adjuvant therapy was that physicians considered the patients as too fragile after surgery.

CONCLUSIONS

THIS REAL-LIFE COHORT HIGHLIGHTS AN EARLY ADOPTION OF ICIS IN MANAGING PATIENTS WITH LIMITED STAGE RESECTABLE NSCLC IN THE UK, WITH NO MAJOR DIFFICULTIES REPORTED BY CLINICIANS.

REFERENCES

- 1 Novel treatment strategies for early-stage lung cancer : the oncologist's perspective, A. Indini *et al*, Journal of Thoracic Disease 2020
- 2 Survival trends among patients with metastatic NSCLC before and after approval of IO in the US, Y.Wang *et al*, Cancer 2024
- 3 Phase 3 trials of Neoadjuvant, Perioperative and Adjuvant Chemolo for resectable early-stage NSCLC, J. Lee *et al*, JTO Clinical and research reports, 2025

Early and locally advanced NSCLC : ESMO clinical practice guidelines, A.Zer *et al*, ESMO Annals of Oncology 2025

CONTACT INFORMATION

Stéphane DENIAU s.deniau@aplusaresearch.com